Target intelligence / Profile preview

Vascular endothelial growth factor C (VEGF-C) (VEGF-C)

Target
VEGF-C
Molecular classification
Growth factor, Vascular endothelial growth factor family
01

Overview

Vascular endothelial growth factor C (VEGF-C) is a secreted glycoprotein and a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. It is the primary ligand for the receptor tyrosine kinase VEGFR-3 (Flt4) and also binds to VEGFR-2 (KDR) after proteolytic processing [UniProt: P49767]. The fundamental biological role of VEGF-C is the regulation of lymphangiogenesis, the process by which new lymphatic vessels form from pre-existing ones, which is essential for fluid homeostasis and immune surveillance. In oncology, VEGF-C is frequently upregulated by various tumors, where it promotes the expansion of the lymphatic network, thereby facilitating the metastatic spread of cancer cells to regional lymph nodes. Consequently, VEGF-C is a significant therapeutic target; inhibitors such as monoclonal antibodies (e.g., VGX-100) and decoy receptors (e.g., OPT-302) are being developed to block its signaling pathways to treat metastatic cancer and ocular diseases like age-related macular degeneration [: NCT01446146, NCT03345069]. Beyond its role in vessel growth, VEGF-C is also involved in modulating inflammatory responses and has been explored for its potential pro-lymphangiogenic effects in treating lymphedema.

Other names
Flt4 ligandVascular endothelial growth factor-related proteinVRPVEGFC
02

Mechanism of action

Neutralization of VEGF-C protein, inhibition of VEGFR-3 and VEGFR-2 activation, and decoy receptor binding (trap mechanism).

03

Biological functions

LymphangiogenesisAngiogenesisCell proliferationCell migrationSignal transduction
04

Disease associations

CancerLymphedemaInflammationCardiovascular diseaseOcular disease
05

Safety considerations

Impaired wound healingPotential for lymphedemaImpact on immune cell traffickingOff-target vascular effects
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

Serum VEGF-C levelsVEGFR-3 expressionLymphatic vessel density

Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Vascular endothelial growth factor C (VEGF-C) (VEGF-C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vascular endothelial growth factor C (VEGF-C) (VEGF-C).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call